Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma after Anthracycline-Based Chemotherapy

Kathryn J. Ruddy, Lindsey R. Sangaralingham, Holly Van Houten, Somaira Nowsheen, Nicole P Sandhu, Javid Moslehi, Heather Neuman, Ahmedin Jemal, Tufia C. Haddad, Anne H. Blaes, Hector R. Villarraga, Carrie Thompson, Nilay D. Shah, Joerg Herrmann

Research output: Contribution to journalArticle

Abstract

Background: The National Comprehensive Cancer Network and American Society of Clinical Oncology recommend consideration of the use of echocardiography 6 to 12 months after completion of anthracycline-based chemotherapy in at-risk populations. Assessment of BNP (B-type natriuretic peptide) has also been suggested by the American College of Cardiology/American Heart Association/Heart Failure Society of America for the identification of Stage A (at risk) heart failure patients. The real-world frequency of the use of these tests in patients after receipt of anthracycline therapy, however, has not been studied previously. Methods and Results: In this retrospective study, using administrative claims data from the OptumLabs Data Warehouse, we identified 31 447 breast cancer and lymphoma patients (age ≥18 years) who were treated with an anthracycline in the United States between January 1, 2008 and January 31, 2018. Continuous medical and pharmacy coverage was required for at least 6 months before the initial anthracycline dose and 12 months after the final dose. Only 36.1% of patients had any type of cardiac surveillance (echocardiography, BNP, or cardiac imaging) in the year following completion of anthracycline therapy (29.7% echocardiography). Surveillance rate increased from 37.5% in 2008 to 42.7% in 2018 (25.6% in 2008 to 40.5% echocardiography in 2018). Lymphoma patients had a lower likelihood of any surveillance compared with patients with breast cancer (odds ratio, 0.79 [95% CI, 0.74-0.85]; P<0.001). Patients with preexisting diagnoses of coronary artery disease and arrhythmia had the highest likelihood of cardiac surveillance (odds ratio, 1.54 [95% CI, 1.39-1.69] and odds ratio, 1.42 [95% CI, 1.3-1.53]; P<0.001 for both), although no single comorbidity was associated with a >50% rate of surveillance. Conclusions: The majority of survivors of breast cancer and lymphoma who have received anthracycline-based chemotherapy do not undergo cardiac surveillance after treatment, including those with a history of cardiovascular comorbidities, such as heart failure.

Original languageEnglish (US)
Article numbere005984
JournalCirculation: Cardiovascular Quality and Outcomes
DOIs
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma after Anthracycline-Based Chemotherapy'. Together they form a unique fingerprint.

  • Cite this